Inside informationEnglish
NFL Biosciences presents the immunological analysis results of its phase 2 CESTO II study confirming the efficacy of NFL-101, its first-in-class treatment for tobacco addiction
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- NFL Biosciences
- Filed
- 24/03/2025, 17:46
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 077914_20250324